Translocation renal cell carcinoma (tRCC) is a rare subtype of renal cell carcinoma occurring in less than 5 percent of patients. Initially found primarily in children, incidence of tRCC found in adults is rising. Because it is so rare, research to identify the best treatments for tRCC patients is severely lacking. The Translocation RCC Research Initiative (TRRI) is working to change that! Laura Loughlin, KCCure Director of Patient Engagement, had the opportunity to speak with Dr. James Geller, a tRCC expert at Cincinnati Children’s Hospital and leader of the TRRI. What is the TRRI? The TRRI is a global team of doctors and researchers dedicated to tRCC research to find new and better treatments and improve patient outcomes. Their work in...
NIH Trial – HERV-E TCR Transduced Autologous T Cells in People with Metastatic Clear Cell Kidney Cancer. Good News! Since I last shared news of this exciting clear cell kidney cancer trial it has continued to actively recruit. If you are interested there are still spots available. Eligibility criteria include: Being at least 18, having clear cell RCC, measurable disease progression in the last six months; and being positive for HLA-A 11:01. HLA-A 11:01 is only present in a subset of clear cell RCC patients. The NIH, at no charge, can arrange testing for you if you are interested in finding out if you are positive for HLA-A 11:01. Additionally, there are some eligibility requirements related to prior treatments. The trial involves...
This chart lays out non-clear cell response rates for two kidney cancer clinical trials that were presented at ASCO-GU 2019. The Keynote 427 trial for pembrolizumab (Keytruda) as monotherapy and the Calypso trial combining savolitinib (MET inhibitor) and durvalumab (PD-1 inhibitor).
In the Making a Difference series, KCCure’s Director of Patient Engagement, Laura Loughlin will be highlighting organizations making a difference in Kidney Cancer research. In this first article, we’re profiling work being done at the Broad Institute researching rare kidney cancer. The Broad Institute of Cambridge and Harvard Located in Cambridge, MA the Broad is a non-profit research organization partnered with MIT, Harvard and the five Harvard teaching hospitals. On October 18th I had the opportunity to visit the Broad. I attended a Pre-Launch Workshop for the Rare Cancer Dependency Map Initiative. This initiative provides a patient driven research platform seeking treatments for rare kidney cancers. The research starts with patients’ authorizing donation of fresh tissue...
For the second year in a row, KCCure represented kidney cancer patients at the annual meeting for the American Urological Association. This year, KCCure was instrumental in planning for the meeting by serving on the AUA Steering Committee for Patient Advocacy Efforts.
“Today’s decision by the FDA is a game-changer for patients and physicians managing advanced kidney cancer,” said Hans Hammers M.D., Ph.D., KCCure co-founder and senior co-author of the clinical study for the combination.
KCCure joined with twelve other kidney cancer advocacy organizations urging Congress to double kidney cancer research funding for the Kidney Cancer Research Program (KCRP) administered by the Congressionally Directed Medical Research Program (CDMRP).
Today's Voice of Kidney Cancer is Dr. Elizabeth (Lisa) Henske, who runs the Henske Lab at Brigham and Women's Hospital and Harvard Medical School in Boston. One of her principal areas of research is chromophobe renal cell carcinoma (chRCC). She's also one of the newest members of the KCCure scientific advisory board. We're grateful to Dr. Henske for donating her time to answer a few questions about her work in chRCC.
The 2018 Genitourinary (GU) Cancers Symposium is a three-day scientific and educational meeting focusing on research and clinical applications in GU cancers (which includes kidney, prostate and bladder). For the second year in a row, KCCure participated in this important kidney cancer conference.
Register today to learn more about how to apply for new kidney cancer funding! Kidney cancer research funding will be provided for the fiscal year 2017 (FY17) through a new, $10 million, stand-alone program in the Department of Defense Congressionally Directed Medical Research Programs.